Galecto Newsroom

Galecto Anticipates That Its Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Operating Expenses and Cap Requirements for at Least the Next Twelve Mos >GLTO

Dow JonesNov 1 20:31

Galecto Cash, Cash Equivalents, and Investments as of Sept 30 Were $19.7M >GLTO

Dow JonesNov 1 20:31

Express News | Galecto Reports Third Quarter 2024 Financial Results

BreakingsNov 1 20:30

Galecto 3Q Loss/Shr $3.39 >GLTO

Dow JonesNov 1 20:30

Galecto 3Q Loss $3.88M >GLTO

Dow JonesNov 1 20:30

Press Release: Galecto Reports Third Quarter 2024 Financial Results

Dow JonesNov 1 20:30

Galecto | 10-Q: Q3 2024 Earnings Report

SECNov 1 20:02 · Announcements

Galecto Is Maintained at Outperform by Oppenheimer

Dow JonesOct 17 21:32 · Ratings

Galecto Analyst Ratings

BenzingaOct 17 21:20 · Ratings

Oppenheimer Maintains Galecto(GLTO.US) With Buy Rating, Cuts Target Price to $10

Futu NewsOct 17 20:34 · Ratings

Express News | Galecto Inc : Oppenheimer Raises Target Price to $10 From $9

BreakingsOct 17 20:15

Oppenheimer Sticks to Its Buy Rating for Galecto (GLTO)

TipRanksOct 17 20:07 · Ratings

Express News | Galecto Strengthens Board of Directors With Appointment of DR. Amy Wechsler

BreakingsOct 15 20:30

Press Release: Galecto Strengthens Board of Directors With Appointment of Dr. Amy Wechsler

Dow JonesOct 15 20:30

Sector Update: Health Care Stocks Softer Monday Afternoon

MT NewswiresOct 8 01:58

12 Health Care Stocks Moving In Monday's Intraday Session

BenzingaOct 8 00:31

Why Galecto (GLTO) Shares Are Down 27% Today

BenzingaOct 7 23:23

Galecto To Focus On Clinical Stage Compound GB1211; Obtains Global Rights To BRM-1420

RTTNewsOct 7 21:51

Galecto Shares Shares Are Trading Lower. The Company Issued 62,594 Shares of Common Stock and 160,562 of Preferred Convertible Shares to Bridge Medicine as Part of Their Acquisition for the Rights to BRM-1420.

BenzingaOct 7 21:48

Galecto Shares Slide on Leukemia Treatment Rights Acquisition

WSJOct 7 21:21